The presentation will share Almac's latest developments in first-in-class DUB inhibitors
Almac Discovery, a biopharmaceutical company with a key research focus in the area of deubiquitylating enzyme therapeutic discovery, has had its work recognised by an invitation to deliver a podium presentation at the 8th Proteasome and Autophagy Congress held 25 – 27 April in Clermont-Ferrand, France.
The conference theme is strongly aligned with Almac Discovery’s research strengths where it maintains a team of experts dedicated to research into the tractability of DUBs/USPs. Gerald Gavory, Head of Biology, will give an oral presentation on the “Discovery and development of first-in-class USP19 inhibitors” to demonstrate the potential opportunities for the development of new therapeutics with applications in neurodegenerative and muscle wasting disorders.
Almac Discovery has developed its UbiPlex platform for the discovery of hits to this challenging and novel class of DUB/USP targets which cover a broad range of potential clinical indications from neurodegeneration to cancer and infection.
The company has a goal to spearhead the discovery of DUB based therapeutics and to broaden knowledge of this class of targets. The USP19 inhibitors, which will be described, demonstrate high potency in muscle cells together with exquisite selectivity and, taken together with their inactive control compounds, should prove excellent tools in unlocking the biology of USP19.
In addition, Ewelina Rozycka will present a poster covering additional deubiquitylating enzyme discovery work during the conference.
Should you wish to meet with a representative during Proteasome & Autophagy Congress please contact Martin Wiles, VP Business Development & Licensing – email@example.com.